blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2877156

EP2877156 - CHONDROITIN COMPLEXES FOR TRANSCUTANEOUS ABSORPTION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.11.2020
Database last updated on 13.09.2024
FormerThe patent has been granted
Status updated on  05.12.2019
FormerGrant of patent is intended
Status updated on  24.07.2019
FormerExamination is in progress
Status updated on  02.02.2018
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): AL, MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Altergon S.A.
Via Dogana Vecchia 2
6900 Lugano / CH
[2020/01]
Former [2015/23]For all designated states
Altergon S.a.
Via Dogana Vecchia 2
6900 Lugano / CH
Inventor(s)01 / DE ROSA, Mario
c/o ALTERGON S.A.
Via Dogana Vecchia 2
6900 Lugano / CH
02 / SCHIRALDI, Chiara
c/o ALTERGON S.A.
Via Dogana Vecchia 2
6900 Lugano / CH
 [2015/23]
Representative(s)Bianchetti & Minoja with Trevisan & Cuonzo IPS SRL
Via Plinio, 63
20129 Milano / IT
[N/P]
Former [2015/23]Bianchetti Bracco Minoja S.r.l.
Via Plinio, 63
20129 Milano / IT
Application number, filing date13747807.925.07.2013
[2020/01]
WO2013EP65733
Priority number, dateIT2012MI0131627.07.2012         Original published format: IT MI20121316
[2015/23]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014016380
Date:30.01.2014
Language:EN
[2014/05]
Type: A1 Application with search report 
No.:EP2877156
Date:03.06.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 30.01.2014 takes the place of the publication of the European patent application.
[2015/23]
Type: B1 Patent specification 
No.:EP2877156
Date:01.01.2020
Language:EN
[2020/01]
Search report(s)International search report - published on:EP30.01.2014
ClassificationIPC:A61K45/06, A61K9/06, A61K47/36, A61K9/00, A61K47/61, A61K31/196, A61K31/407
[2019/32]
CPC:
A61K31/407 (EP,RU,US); A61K31/196 (EP,RU,US); A61K47/36 (EP,RU,US);
A61K47/61 (EP,RU,US); A61K8/735 (EP,US); A61K9/0014 (EP,RU,US);
A61K9/06 (EP,RU,US); A61Q19/08 (EP,US); A61K2800/54 (EP,RU,US) (-)
Former IPC [2015/23]A61K9/06, A61K47/36, A61K9/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/23]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:CHONDROITINKOMPLEXE ZUR TRANSKUTANEN AUFNAHME[2015/23]
English:CHONDROITIN COMPLEXES FOR TRANSCUTANEOUS ABSORPTION[2015/23]
French:COMPLEXES DE CHONDROÏTINE POUR UNE ABSORPTION TRANSCUTANÉE[2015/23]
Entry into regional phase09.01.2015National basic fee paid 
09.01.2015Designation fee(s) paid 
09.01.2015Examination fee paid 
Examination procedure08.05.2014Request for preliminary examination filed
International Preliminary Examining Authority: EP
09.01.2015Examination requested  [2015/23]
28.07.2015Amendment by applicant (claims and/or description)
31.01.2018Despatch of a communication from the examining division (Time limit: M04)
19.03.2018Reply to a communication from the examining division
02.10.2018Despatch of a communication from the examining division (Time limit: M04)
14.01.2019Reply to a communication from the examining division
25.07.2019Communication of intention to grant the patent
22.11.2019Fee for grant paid
22.11.2019Fee for publishing/printing paid
22.11.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  31.01.2018
Opposition(s)02.10.2020No opposition filed within time limit [2020/50]
Fees paidRenewal fee
24.07.2015Renewal fee patent year 03
22.07.2016Renewal fee patent year 04
21.07.2017Renewal fee patent year 05
24.07.2018Renewal fee patent year 06
22.07.2019Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL01.01.2020
EE01.01.2020
HR01.01.2020
LT01.01.2020
LV01.01.2020
MC01.01.2020
MK01.01.2020
MT01.01.2020
RO01.01.2020
RS01.01.2020
SE01.01.2020
SI01.01.2020
SM01.01.2020
BG01.04.2020
NO01.04.2020
IS01.05.2020
PT27.05.2020
[2022/31]
Former [2022/28]EE01.01.2020
HR01.01.2020
LT01.01.2020
LV01.01.2020
MC01.01.2020
MT01.01.2020
RO01.01.2020
RS01.01.2020
SE01.01.2020
SI01.01.2020
SM01.01.2020
BG01.04.2020
NO01.04.2020
IS01.05.2020
PT27.05.2020
Former [2021/13]EE01.01.2020
HR01.01.2020
LT01.01.2020
LV01.01.2020
MC01.01.2020
RO01.01.2020
RS01.01.2020
SE01.01.2020
SI01.01.2020
SM01.01.2020
BG01.04.2020
NO01.04.2020
IS01.05.2020
PT27.05.2020
Former [2020/50]EE01.01.2020
HR01.01.2020
LT01.01.2020
LV01.01.2020
RO01.01.2020
RS01.01.2020
SE01.01.2020
SM01.01.2020
BG01.04.2020
NO01.04.2020
IS01.05.2020
PT27.05.2020
Former [2020/48]HR01.01.2020
LT01.01.2020
LV01.01.2020
RO01.01.2020
RS01.01.2020
SE01.01.2020
SM01.01.2020
BG01.04.2020
NO01.04.2020
IS01.05.2020
PT27.05.2020
Former [2020/40]HR01.01.2020
LT01.01.2020
LV01.01.2020
RS01.01.2020
SE01.01.2020
BG01.04.2020
NO01.04.2020
IS01.05.2020
PT27.05.2020
Former [2020/39]HR01.01.2020
LT01.01.2020
LV01.01.2020
RS01.01.2020
SE01.01.2020
BG01.04.2020
NO01.04.2020
PT27.05.2020
Former [2020/37]HR01.01.2020
LT01.01.2020
LV01.01.2020
RS01.01.2020
SE01.01.2020
NO01.04.2020
PT27.05.2020
Former [2020/36]LT01.01.2020
RS01.01.2020
NO01.04.2020
PT27.05.2020
Former [2020/35]LT01.01.2020
NO01.04.2020
Cited inInternational search[X]EP1582214  (GENEVRIER LAB [FR]) [X] 1-7* page 7; claims 1-10 *;
 [X]EP2106798  (NESTEC SA [CH]) [X] 1-7 * pages 7-8; claims 2, 3, 6, 11-13 *
ExaminationUS2003104601
 EP1582214
 EP2106798
by applicantUS5639738
 US5792753
 US5852002
 WO0102597
 US6288044
 WO0180810
 EP1282684
 US2003104601
 US2003109693
 JP2004024208
 US6777398
 US2005164984
 US2005266460
 US2006052335
 US2006057697
 US2007015249
 WO2007023867
 US2007059805
 WO2007058252
 US7232676
 WO2007069693
 EP1832662
 US7273729
 WO2007145197
 EP1950308
 WO2010136435
 US2011244520
    - SUGAHARA ET AL., J. BIOL. CHEM., (1996), vol. 271, pages 26745 - 54
    - SUGUMARAN; SILBERT, J. BIOL. CHEM., (19901025), vol. 265, no. 30, pages 18284 - 8
    - RODRIGUEZ ET AL., EUR. J. BIOCHEM., (1988), vol. 177, pages 117 - 124
    - MANZONI ET AL., BIOTECHNOLOGY LETTERS, (1996), vol. 18, pages 383 - 386
    - "Hyaluronan: Biomedical", BROWN ET AL., Medical and Clinical Aspects, CAMBRIDGE: WOODHEAD PUBLISHERS, (2002), pages 249 - 256
    - BROWN ET AL., Hyaluronan in Drug Delivery, ROYAL SOCIETY OF MEDICINE PRESS, (1995), pages 48 - 52
    - BROWN ET AL., Hyaluronan in Drug Delivery, ROYAL SOCIETY OF MEDICINE PRESS, (1995), pages 53 - 71
    - BROWN ET AL., INT. J. TISSUE REACTIONS- EXP. CLIN. ASPECTS, (1995), vol. 17, pages 133 - 140
    - BROWN; MOORE, Hyaluronan in Drug Delivery, ROYAL SOCIETY OF MEDICINE PRESS, (1996), pages 121 - 131
    - MCEWAN; SMITH, AUST. J. DERM, (1997), vol. 38, pages 187 - 189
    - NAZIR ET AL., PHARM. SCI., (2001), vol. 3, page 1429
    - MCEWAN; SMITH, AUST. J. DERM., (1997), vol. 38, pages 187 - 189
    - WOLF ET AL., INT. J. DERMATOL., (2001), vol. 40, pages 709 - 713
    - LIN; MAIBACH, Hyaluronan in Drug Delivery, R.S. M. PRESS., pages 167 - 174
    - BROWN ET AL., J. INVEST. DERMATOL., (1999), vol. 113, pages 740 - 746
    - "Hyaluronan: Biomedical", BROWN ET AL., Medical and Clinical Aspects, WOODHEAD PUBLISHERS, pages 249 - 256
    - BROWN; MARTIN, INT. J. PHARM., (2001), vol. 225, pages 113 - 121
    - PROC. MILLEN. CONG. PHARMA. SCI., (2000), page A80
    - BROWN ET AL., INTERNATIONAL J. OF PHARMACEUTICS, (2001), vol. 225, pages 113 - 121
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.